Scientific studies confirm Uronext’s benefits for treating urinary tract infections

The journal of Experimental and Clinical Urology published two papers compiling the findings derived from studies exploring the complex drug Uronext® applied to protect the urinary tract. The complex has demonstrated positive anti-adhesive and antibacterial effects against uropathogens in patients with recurrent lower urinary tract infections (UTIs).

UTIs account for more than 10.5 million visits to urologists each year^[1]. They are most common in women suffering from uncomplicated bladder infections. One of the methods utilized to treat UTIs is antibiotic therapy, but experts are concerned that regular antibiotic use may develop resistant strains of microorganisms. Scientists are looking for other methods to protect the urinary tract from infections.

The first study, directed by M.N. Slesarevskaya, examined 124 strains of uropathogens isolated from the urine of women with recurrent UTIs. The results demonstrated that the combination of cranberry extract, D-mannose and vitamin D3 (all part of Uronext® formula) has a direct antibacterial effect on 53.7% of gram-negative and 51.7% of gram-positive microorganisms. Thus athogenetic treatment of reccurent UTI's with dietary supplement Uronext® seem to be rationale.

The second study included a literature review acknowledging the benefits of D-mannose and cranberry proanthocyanidins have in UTI prevention.

Given the increasing antibiotic resistance, safe and effective methods that can be used to prevent recurrent UTIs are highly sought. These studies produced the results which open up the new horizons in urinary tract protection options.